In vitro activities of levofloxacin in combination with fosfomycin against  staphylococcus aureus

Abstract

Abstract: AIM: To investigate the in vitro bactericidal activity of levofloxacin alone and combined with fosfomycin against 3 strains MSSA and 1 stain MRSA.METHODS: Three MSSA strains and 1 MRSA from clinical specimens were used in this study. Time-kill curve method was carried out with different concentration of the two drugs both alone and in combination.RESULTS: Levoloxacin alone showed a concentration-dependent time-kill curve against three strains of MSSA, fosfomycin showed a nonconcentration-dependent time-kill curve. Neither levofloxacin nor fosfomycin alone inhibited bacterial growth at 1/4 MIC; but the combination of this two drugs at 1/4 the respective MIC showed a synergistic bactericidal effect, a 2-3 log₁₀ decrease with respect to the most active antibiotic alone.CONCLUSION: The combination of subinhibitory concentrations of levofloxacin and fosfomycin presented synergism,exerting a bactericidal effect. The combination also has a bactericidal effect against MRSA.

Key words: Staphylococcus aureus, Levofloxacin, Fosfomycin , Time-kill curve

CLC Number:

R965.2

SONG Xiu-jie, JU Hong-mei, YU Xu-hong, LIN De-feng, WANG Rui, LIU You-ning. In vitro activities of levofloxacin in combination with fosfomycin against staphylococcus aureus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1388-1394.

References

[1] 汪复.2006 年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2008,1(8):1-9.
[2] CDC.Staphylococcus aureus resistant to vancomycin-united states[J].MMWR,2002,51(26):565-567.
[3] Lodise TP, Graves J,Evans A.Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin[J]. Antimicrob Agents Chemother,2008,52(9):3315-3320.
[4] Kumon H, Ono N, Iida M,et al. Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm[J].Antimicrob Agents Chemother, 1995 ,39(5):1038-1044.
[5] Nakazawa H, Kikuchi Y, Honda T,et al.Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin[J]. J Infect Chemother ,2003,9(4):304-309.
[6] Mikuniya T, Kato Y, Kariyama R,et al.Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm[J].Acta Med Okayama, 2005,5(59):209-216.
[7] Zeitlinger M, Marsik C, Steiner I,et al .Immunomodulatory effects of fosfomycin in an endotoxin model in human blood [J]. J Antimicrob Chemother,2007,59(2):219-223.
[8] 徐修礼,胡晓卫,孙怡群,等.万古霉素和左氧沙星对金黄色葡萄球菌的体外联合抗菌活性研究[J].中国药物与临床,2007,7(7):541-541.
[9] 宋秀杰,刘又宁,鞠红梅.左氧沙星与磷霉素联用对30株金黄色葡萄球菌的抗菌活性[J].中国临床药理学杂志,2009,6(25):505-508.
[10] Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A,et al.In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible staphylococcus aureus[J]. Rev Esp Quimioterap Septiembre,2006,19 (3): 252-257.
[11] 叶英,李家斌.磷霉素在治疗肝硬化并发自发性腹膜炎中的协同作用[J].中国社区医师,2008,24(4):25.
[12] Lau WY, Teoh-chan CH, Fan ST.In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia[J]. J Hyg (Lond),1986, 93(3): 419-423.
[13] 连家建,唐青云.磷霉素可减轻其他药物引起的不良反应[J].国外医药抗生素分册,2002,23(1):38.
[14] 王睿.临床抗感染药物治疗学[M].北京:人民卫生出版社,2006:134-136.
[15] Leonard SN, Kaatz GW,Rucker LR,et al.Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus[J]. J Antimicrob Chemother,2008, 62(6):1305-1310.
[16] Xiong YQ, Potel G, Caillon J, et al.Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother,1995,35(2):496-499.
[17] Kumon H, Ono N, Iida M, et al.Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm[J].Antimicrob Agents Chemother,1995 ,39(5):1038-1044.
[18] Nakazawa H, Kikuchi Y , Honda T,et al.Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA)by combination with fosfomycin[J]. J Infect Chemother,2003, 9(4):304-309.
[19] Doss SA, Tillotson GS, Amyes SG.Effect of subinhibitory concentrations of antibiotics on the virulence of Staphylococcus aureus[J]. J Appl Bacteriol,1993,75(2):123-128.
[20] Drlica K. A strategy for fighting antibiotic resistance[J].ASM News,2001,67 :272-331.

In vitro activities of levofloxacin in combination with fosfomycin against staphylococcus aureus

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[2]	ZHANG Peng, WANG Zishu, XU Lihong, YIN Xiangnan, HU Wen, CHEN Chunlin. Synergistic antibacterial effect of ursolic acid combined with fusidic acid on Staphylococcus aureus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 608-613.
[3]	LI Xiaoning, YU Xiao, HUANG Chenlei, CAO Ruonan, LI Jie, ZHU Guoping. Inhibitory and scavenging ability of ambroxol combined with levofloxacin on the bacterial biofilm of Klebsiella pneumoniae [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1103-1110.
[4]	XU Jia, HUANG Qi, YANG Zhiling . Evaluation of clinical rationality of linezolid in our hospital in 2016 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 110-115.
[5]	JIANG Cheng, LV Jiangang, LI Fangqiong, YE Zuowu, LU Chunfang, LI Gonghua. Correlation between detection rate of clindamycin-resistant Staphylococcus aureus and utilization of antibacterial drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 439-442.
[6]	YE Ying. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 661-668.
[7]	HUA Jun-yan, TIAN Wei-qiang, ZHU Ya-yan, YU Hui-kang. Efficacy and plasma concentration analysis of Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(6): 673-677.
[8]	LIANG Bei-bei, WANG Rui, BAI Nan, CAI Yun. Mutant prevention concentrations study of linezolid and vancomycin against methicillin-resistant staphylococcus aureus isolates [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 251-254.
[9]	YANG Li-jie, LI Xiao-meng, GUO Mei-hua. Analysis of adverse effects of fosfomycin injection in 148 cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(3): 320-322.
[10]	WANG Hui, MENG Jing-ru, CHEN Tao, JIA Ming, HE Gong-hao, MA Xue, LUO Xiaoxing. Reversal of antibiotic resistance methicillanin-resistant staphylococcus aureus by polyethyleneimine-phosphothioate oligodeoxynucleotide nanometer particle [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(1): 31-35.
[11]	CUI Jun-chang, LIU You-ning, WANG Rui, TONG Wei-hang, LIANG Bei-bei. Correlation of levofloxacin pharmacokinetic/pharmacodynamic parameters with selection of staphylococcus aureus resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(9): 989-992.
[12]	LI Zhao-xia, LIU You-ning, WANG Rui, TONG Wei-hang, CHENG Shi-hu. Preliminary study for narrowing mutant selection window of staphylococcus aureus by combination of levofloxacin and Vancomycin in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 911-914.
[13]	CHU Ji-hong, JU Wen-zheng, XU Mei-juan, WU Ting, WEI Xi, TAN Heng-shan, JIANG Meng, XIONG Ning-ning. Pharmacokinetics of levofloxacin hydrochloride soft capsules, hard capsules and tablets in Chinese healthy volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(6): 710-713.
[14]	CUI Jun-chang, LIU You-ning, WANG Rui, TONG Wei-hang, LI Zhao-xia. Development of tissue cage infection model and study of efficacy of levofloxacin in treatment of staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 291-294.
[15]	ZHANG Xiang-wu, ZHENG Jiang, FU Jian-feng, GUO Yi-bin, CHEN Yi-guo, LU Yong-ling. Isolation purification and identification of soluble peptidoglycan from staphylococcus aureus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 321-323.